Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan for Prevention of ARDS in Hospitalized COVID-19 Patients
2020-001320-34Phase 4Terminated
- Sponsor
- Radboudumc
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing Valsartan with Placebo (2 arms). Primary endpoint: Composite severe outcome within 14 days. Started Mar 2020; status: terminated.
02
Drugs
valsartan
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-001320-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001320-34.